{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:38:19Z","timestamp":1769603899727,"version":"3.49.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.chest.2024.10.048","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:18:42Z","timestamp":1744114722000},"page":"e109-e112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Gain-of-Function Mutation in Mechanistic Target of Rapamycin Results in a Tuberous Sclerosis Complex-Like Manifestation of Parenchymal Lung Disease"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8044-4108","authenticated-orcid":false,"given":"Thomas C.","family":"Bolig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjana V.","family":"Yeldandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-9525","authenticated-orcid":false,"given":"Jane E.","family":"Dematte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-0845","authenticated-orcid":false,"given":"Anthony J.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2024.10.048_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.chest.2024.10.048_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.35","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.chest.2024.10.048_bib3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00408-015-9750-6","article-title":"Tuberous sclerosis complex: state-of-the-art review with a focus on pulmonary involvement","volume":"193","author":"von Ranke","year":"2015","journal-title":"Lung"},{"issue":"6","key":"10.1016\/j.chest.2024.10.048_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jjco\/hyn042","article-title":"Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis: differentiation from multiple atypical adenomatous hyperplasia","volume":"38","author":"Kobashi","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"10.1016\/j.chest.2024.10.048_bib5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","article-title":"A\u00a0diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity","volume":"4","author":"Grabiner","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.chest.2024.10.048_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.636037","article-title":"Mechanistic target of rapamycin inhibitors in renal cell carcinoma: potential, limitations, and perspectives","volume":"9","author":"Faes","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.chest.2024.10.048_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmcr.2021.101526","article-title":"Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex","volume":"34","author":"Shoji","year":"2021","journal-title":"Respiratory Medicine Case Reports"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224054606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224054606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T20:03:15Z","timestamp":1747857795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224054606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0012369224054606"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.10.048","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Gain-of-Function Mutation in Mechanistic Target of Rapamycin Results in a Tuberous Sclerosis Complex-Like Manifestation of Parenchymal Lung Disease","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.10.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}